Please login to the form below

Not currently logged in
Email:
Password:

US biotech Translate Bio appoints Daniella Beckman

She joins the board of directors

Daniella BeckmanTranslate Bio has appointed Daniella Beckman to its board of directors and she will also serve at the US biotech as chairperson of its board’s audit committee.

Beckman has over 15 years’ of financial and operational experience and she currently provides consulting and interim chief financial officer services for early-stage biotech companies, including Tango Therapeutics and Neon Therapeutics.

She said: “I am thrilled to join the Translate Bio board of directors at such a pivotal time for the organisation, I look forward to supporting the company being a part of a dedicated team focused on developing innovative products for genetic diseases.”

Prior to her new role, Beckman was chief financial officer of Idenix Pharmaceuticals - until it was acquired by Merck in 2014 - where she oversaw finance, treasure, capital raises and investor relations.

She has also held various finance positions at Coley Pharmaceuticals - which was acquired by Pfizer in 2008 - and Biogen Idec.

Ronald Renaud, chief executive officer, Translate Bio, said: “Daniella joins our board of directors at an exciting time for Translate Bio. Her financial and operational expertise will be vital as we continue to build the company and bring our first product candidate into the clinic for the treatment of cystic fibrosis in early 2018.”

18th October 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....